Hypertension secondary to scavenging of NO remains a limitation in the use of HBOCs (haemoglobin-based oxygen carriers). Recent studies suggest that nitrite reduction to NO by deoxyhaemoglobin supports NO signalling. In the present study we tested whether nitrite would attenuate HBOC-mediated hypertension using HBOC-201 (Biopure), a bovine cross-linked, low-oxygen-affinity haemoglobin. In a similar way to unmodified haemoglobin, deoxygenated HBOC-201 reduced nitrite to NO with rates directly proportional to the extent of deoxygenation. The functional importance of HBOC-201-dependent nitrite reduction was demonstrated using isolated aortic rings and a murine model of trauma, haemorrhage and resuscitation. In the former, HBOC-201 inhibited NO-donor and nitrite-dependent vasodilation when oxygenated. However, deoxygenated HBOC-201 failed to affect nitrite-dependent vasodilation but still inhibited NO-donor dependent vasodilation, consistent with a model in which nitrite-reduction by deoxyHBOC-201 counters NO scavenging. Finally, resuscitation using HBOC-201, after trauma and haemorrhage, resulted in mild hypertension (∼ 5-10 mmHg). Administration of a single bolus nitrite (30-100 nmol) at the onset of HBOC-201 resuscitation prevented hypertension. Nitrite had no effect on mean arterial pressure during resuscitation with LR (lactated Ringer's solution), suggesting a role for nitrite-HBOC reactions in attenuating HBOC-mediated hypertension. Taken together these data support the concept that nitrite can be used as an adjunct therapy to prevent HBOC-dependent hypertension.
INTRODUCTION
Safety concerns coupled with a lack of supply of donated RBCs (red blood cells) have led to a great deal of interest in the development of blood substitutes as alternative resuscitative agents. Such resuscitative agents would need to be capable of simultaneously improving vascular function and tissue perfusion/oxygenation. The current generation of so-called HBOCs (haemoglobin-based oxygen carriers) comprise haemoglobins from different species (human and bovine) that have been chemically modified to improve structural stability (thereby extending circulatory half-life and minimizing renal toxicity) and to modulate oxygen affinity (to counter the higher oxygen affinity of cell-free haemoglobin compared with erythrocytic haemoglobin) [1, 2] . Despite extensive efforts in their development, previous studies have indicated there are major additional concerns with the clinical use of HBOCs [3] [4] [5] [6] [7] [8] . These concerns stem from the ability of cell-free haemoglobins to stimulate pro-oxidative reactions and scavenge NO [3] [4] [5] [6] [7] [8] , an endogenously produced free radical that plays critical roles in vascular homoeostasis [9, 10] . In this way, HBOCs may promote hypertensive and pro-oxidative responses and thereby may exacerbate underlying tissue injury.
NO is instrumental in vascular homoeostasis mechanisms controlling blood flow, regulating mitochondrial respiration and maintaining an anti-inflammatory and anti-thrombotic environment [9, 10] . The critical role for NO is indicated by the association between loss of, or aberrant, NO-dependent signalling and the pathogenesis of a variety of diseases including hypertension, atherosclerosis and ischemia-reperfusion injury [11] . Cell-free haemoglobin, in either its oxygenated or deoxygenated state, rapidly reacts with NO (k = ∼ 10 7 M −1 · s −1 ) [12] , which coupled with the relatively high concentrations of haem (at the mM level) that arise from HBOC administration during resuscitative therapies [8] , results in a significant inhibition of NO signalling that manifests acutely with a hypertensive response. Whereas this may be of benefit in certain traumatic injuries e.g. traumatic brain injury, NO scavenging is generally considered to be detrimental and this property remains a significant problem in the therapeutic development of HBOCs [13] .
Recent concepts suggest that the inorganic anion nitrite represents a reservoir for NO bioactivity during hypoxia/ischemia, both in tissues and the vasculature [14 -18] . In this paradigm, nitrite is reduced by one electron to form NO via mechanisms that are activated during hypoxia/ischemia. Nitrite-derived NO restores NO signalling which leads to cytoprotection in a variety of pathologies (e.g. ischemia/reperfusion injury, haemorrhagic stroke, hypoxic pulmonary hypertension and hypertension) and stimulates NO-dependent physiological responses (e.g. angiogenesis) (reviewed in [13, [16] [17] [18] [19] ). How nitrite is reduced to NO during hypoxia remains an active area of investigation with the precise mechanism probably depending upon the specific tissue and degree of hypoxia. In the vascular compartment previous studies have suggested that the reaction of nitrite with deoxyhaemoglobin is important [20] [21] [22] [23] [24] [25] [26] . Specifically, this involves the combination of hypoxia (or more precisely hypoxaemia), deoxygenated RBCs or haemoglobin and nitrite stimulated NO-dependent vasodilatation via activation of soluble guanylate cyclase and formation of cGMP [21] . This socalled nitrite reductase activity of deoxyhaemoglobin should be contrasted with the nitrite oxidase activity of oxyhaemoglobin as shown in the following equations:
Hb [ where Hb is haemoglobin. Moreover, the nitrite reductase activity of deoxyhaemoglobin is under allosteric control over the haemoglobin oxygen affinity [27] . The latter is indicated in part by the observation that the initial rate of nitrite reduction shows a bell-shaped dependence on haemoglobin fractional saturation, being maximal near the haemoglobin p50 (the partial pressure at which haemoglobin is 50 % saturated). This may allow for a coupled response by which haemoglobin-based oxygen sensing results in NO formation at sites of tissue hypoxia [21, 23] . Interestingly, nitrite alone can stimulate vasodilation of isolated aorta [24, [28] [29] [30] [31] and this is inhibited by addition of cell-free oxyhaemoglobin, consistent with a role for NO in nitrite-dependent vasodilation [24, 29] . However, cell-free deoxyhaemoglobin has no effect, despite being equally competent at inhibiting NO-dependent vasodilation [24, 32] . This would be expected from similar rates of NO scavenging by oxyand deoxyhaemoglobin as shown in the following equations:
where metHb is methaemoglobin. Together, these results suggest that in the presence of nitrite, the nitrite reductase activity of deoxyhaemoglobin creates a balance between NO formation and haem-based NO scavenging that dictates the degree to which NO can stimulate signalling and vasodilation.
The potential for nitrite-derived NO formation by interaction with deoxyhaemoglobin raises an intriguing possibility that coadministration of nitrite with an HBOC may result in NO formation in tissues where HBOCs are significantly deoxygenated. Such co-administration may therefore counteract the NO scavenging effects and thereby attenuate hypertension. In this scenario, therapeutic nitrite can be viewed as an NO-donor. Although many NO-donor compounds have been developed, the advantages of nitrite in this scenario is that nitrite-derived NO would be coupled to HBOC deoxygenation and therefore produce NO at sites where increased blood flow is required. Other NO-donors would lack the site-specific release of NO. Consistent with this concept, recent studies by Yu et al. [33, 34] show that inhaled NO, which increases circulating nitrite concentrations, and reagent nitrite itself can attenuate the hypertensive effects of either murine cell-free tetrameric haemoglobin or HBOC-201 (a glutaraldehyde cross-linked bovine haemoglobin) in a top-load murine model of resuscitation. Moreover, Lui et al. [35] have shown that polyethylene glycol conjugation of α-chain crosslinked haemoglobin, which results in an HBOC with suppressed vasoactivity, increased the rate constant for deoxyhaemoglobinmediated nitrite reduction. This suggests that current strategies used to produce stable HBOC may also be used to modulate its nitrite reductase activity and that increasing such activity may be of clinical benefit in diminishing the pressor effects of HBOC.
In the present study we evaluated the nitrite reductase activity of HBOC-201 (haemoglobin-based oxygen carrier 201; Hemopure ® ), a purified glutaraldehyde-polymerized bovine haemoglobin, and tested the potential for nitrite therapy to attenuate HBOC-201-mediated hypertension in a murine model of traumahaemorrhage and resuscitation. HBOC-201 is 'T'-state stabilized haemoglobin with a higher p50 (i.e. a lower oxygen affinity) of ∼ 38 mmHg at 37
• C, pH 7.4, compared with the native cellfree haemoglobin with a p50 of ∼ 10 mmHg at 37
• C, pH 7.4. HBOC-201 also has an extended shelf-life, does not require cross matching or cold storage, is non toxic and has been shown to be an efficacious resuscitative agent in diverse experimental models of trauma and haemorrhagic shock [36] [37] [38] . However it is also known to cause significant hypertension secondary to scavenging of endogenous NO [36] [37] [38] .
EXPERIMENTAL
For a detailed description of the materials and methods used see the Supplementary Experimental section available at http:// www.BiochemJ.org/bj/422/bj4220423add.htm. All procedures using animals were performed under standard aseptic conditions and according to the University of Alabama at Birmingham institutional animal care committee approved protocols.
Vessel bioassay studies
For all vessel experiments thoracic aortas from male SpragueDawley rats were used as described previously in [24] . Aortic rings in KHB (Krebs-Henseleit buffer) [24] were pretreated with 5 μM indomethacin and 100 μM L-NMMA (N G -monomethyl L-arginine) and equilibrated with 95, 21, 2 or 0 % O 2 gas mixtures containing 5 % CO 2 and balanced with N 2 . Following precontraction with PE (L-phenylephrine) the vasodilatory effects of nitrite or MNO (Mahma NONOate) were determined in the absence or presence of either 20 μM hHb (human haemoglobin) or 20 μM HBOC-201 (all concentrations listed are based on haem), which were added before initiating the dose-response. Vasodilatory effects of the cumulative MNO or nitrite additions were determined by measuring the delta tension and expressing this as a percentage of relaxation with respect to the maximal PE constriction. Cumulative dose-dependent relaxation curves were fitted to a sigmoidal function using GraphPad (GraphPad Software), from which the EC 50 was obtained.
During preliminary vasodilation studies with HBOC-201 it was observed that in the presence of nitrite, but not MNO, HBOC-201 concentrations decreased over time. Concomitant with this decrease HBOC-201 protein precipitates were noticed in the vessel bioassay chambers. As a varying haem concentration will affect both NO scavenging and NO formation processes, and hence the vessel response to vasoactive stimuli, in a subset of experiments we assessed the vasodilatory effect of single doses of nitrite in the absence and presence of HBOC-201. For these experiments, vessels were pre-contracted with PE and pre-equlibirated with the desired O 2 -containing gas. HBOC-201 was then added and 2 min was allowed for HBOC-201 mixing/equilibration. Then a single dose of nitrite was added and changes in vessel tension recorded. Using this protocol no significant loss of HBOC-201 was observed (see the Results section). This process was repeated using different vessel segments and different nitrite doses to assimilate a dosedependence of nitrite-dependent vasodilation in the presence and absence of HBOC-201. No significant loss of HBOC-201 was observed in the MNO-dependent vasodilation experiments, nor was any loss of hHb observed in any experiment.
Assessment of hHb or HBOC-201 concentration and redox/ligation state
Aliquots of hHb or HBOC-201 were collected from vessel bioassay chambers, after equilibration with different O 2 containing gases, immediately before and after addition of either nitrite or MNO. Redox and ligation state was determined by fitting measured, visible spectra to the previously acquired base spectra for oxy-, deoxy-, met-, ferryl-, nitrosyl-and metnitrite forms of both HBOC-201 and hHb, which are all species that may be populated during reaction with nitrite, using a least squares method as described previously in [21] [22] [23] [24] . Preparation of reference spectra is described in the Supplementary Experimental section available at http://www.BiochemJ.org/bj/422/bj4220423add. htm (see Figure 1 (A) for HBOC-201 spectra).
Determination of the nitrite reductase activity of HBOC-201
Rates of deoxyhaem loss at 37
• C were measured to assess the nitrite reductase activity of HBOC-201. A progessive degassing of 30 μM HBOC-201 in PBS, pH 7.4, containing 100 μM DTPA (diethylenetriaminepenta-acetic acid) was performed under a stream of helium or N 2 to obtain a range of O 2 fractional saturations. The resulting solutions were transferred anaerobically to sealed spectrophotometer cuvettes and the visible spectra from 450 to 700 nm were collected immediately before and every 30 s after the addition of 5 mM sodium nitrite (i.e. excess nitrite) for 15 min. Concentrations of deoxyHBOC-201 as a function of time were determined by spectral deconvolution using reference spectra to the different HBOC-201 redox and ligation states listed above and as described in [21] [22] [23] . Rate constants were calculated by dividing the slope of the initial (10 %) linear portion of the curve by the initial concentration of deoxyHBOC and nitrite. Concentrations of nitrosylHBOC-201 were used as an index of NO production and were determined by spectral deconvolution after 720 s of nitrite addition. All nitrite stock solutions were prepared in degassed PBS.
NO detection by chemiluminescence
Direct formation of NO was monitored by ozone-based chemiluminescence using a 280i NO analyser (GE Sievers). A mixture containing 1 mM sodium nitrite in PBS, pH 7.4, with 100 μM DTPA and 50 μl of antifoam (GE Sievers) was equilibrated at 37
• C under anoxic conditions in a sealed chamber directly connected to the analyser before the addition of HBOC-201. Nitric oxide formation was confirmed by the addition of the NO scavenger cPTIO [2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide].
cGMP measurement
Rat aortic rings in KHB were equilibrated with gas mixtures containing 0 and 95 % O 2 , supplemented with 5 % CO 2 , at 37
• C and pH 7.45 in the presence of 5 μM indomethacin, 100 μM L-NMMA, 100 μM IBMX (isobutylmethylxanthine), 100 nM PE and 0.00067 % (v/v) SE-15 antifoam (Sigma-Aldrich). Then 20 μM HBOC-201 was added and allowed to equilibrate for 1 min before the addition of 25 μM nitrite. Rings were collected after 10 min, blotted dry, weighed and frozen in liquid nitrogen. cGMP was measured in ring homogenates by ELISA according to manufacturer's instructions (Cayman Chemical).
Trauma-haemorrhage and resuscitation model
C57Bl/6 male mice were anaesthetized by inhalation of 5 % isofluorane in air. The concentration of isofluorane was then reduced to the minimal concentration for maintenance (<1 %). The abdomen and groins were shaved and washed with 10 % povidone-iodine. A 2 cm midline laparotomy was performed to induce soft-tissue trauma. The incision was closed in two layers (fascia/muscle and skin) and bathed in 1 % lidocaine for analgesia. Both femoral arteries were cannulated with catheters (Braintree Scientific). Systemic arterial pressure was continuously monitored through one arterial line while haemorrhage and resuscitation was performed via the other. Mice were bled over 30 min to a MAP (mean arterial pressure) of 25 + − 5 mmHg. This blood pressure was maintained for a further 60 min by additional bleeding as required. At the end of the 90 min haemorrhagic shock period, animals were resuscitated over 30 min with either LR (lactated Ringer's solution) or HBOC-201 formulation equal to total bleedout volume (approx. 60 % of total blood volume). Then, 100 μl of nitrite was administered intravenously in a bolus form (nitrite stock solutions were 0.1 mM, 0.3 mM, 1 mM or 100 mM) immediately prior to the initiation of HBOC-201 infusion. A further higher dose of nitrite (100 μl of 1 M stock solution) was also evaluated in preliminary experiments (n = 2) but this induced death within the resuscitation phase and was therefore excluded from our analysis (results not shown). All experiments were carried out for at least 120 min post-resuscitation. Arterial blood samples were obtained at designated intervals for nitrite measurement and assessment of paO 2 (arterial partial pressure of O 2 ), paCO 2 (arterial partial pressure of CO 2 ), fractional saturation and methaemoglobin.
Measurement of NO metabolites
Plasma nitrite, S-nitrosothiols and N-nitroso compounds were measured as described previously in [39] . Upon collection, RBCs and plasma were immediately separated by centrifugation at 2000 g for 1 min. Plasma was then mixed 1:1 with a solution containing a final concentration of 1mM NEM (Nethylmaleimide) and 100 μM DTPA. The mixture was incubated at room temperature (22
• C) for 2 min prior to snap freezing in liquid nitrogen. Samples were then thawed on ice and in the dark within 4 h of collection and nitrite, S-nitrosothiol and N-nitroso species measured.
Statistical analysis
Dose-dependent vessel relaxation responses were fitted to sigmoidal curves and the results were analysed by 2-way repeated measures ANOVA with a Bonferroni correction post-test. Changes in circulating nitrite levels during haemorrhagic shock and resuscitation with HBOC-201, with or without exogenous nitrite addition, were analysed by 2-way ANOVA with a Bonferroni correction post-test. To evaluate if nitrite therapy attenuated HBOC-201-mediated hypertension during haemorrhagic shock and resuscitation, repeated-measures ANOVA was determined for each of the three experimental periods (haemorrhage, shock and resuscitation). Statistical significance in vessel bioassays and biochemical experiments was assessed by either repeated-measures ANOVA or one-way ANOVA followed by Bonferroni corrections post-test. P values less than 0.05 were considered significant in all cases and analyses were performed using GraphPad Prism Software. 
RESULTS

Nitrite reduction by HBOC-201
We first tested whether HBOC-201 could reduce nitrite and whether this process is regulated by O 2 fractional saturation. Nitrite was added to HBOC-201 at different O 2 saturations and changes in visible absorbance spectra were followed as a function of time. Figure 1(B) shows a representative experiment performed at 60 % O 2 saturation. Time-dependent changes in deoxyHBOC-201 were calculated to assess the nitrite reductase activity ( Figure 1C ) from experimentally measured spectra by least squares deconvolution (shown in Figure 1A ). Figure 1(D) shows the initial rate and calculated rate constant for nitrite reduction (using initial nitrite and deoxyhaemoglobin concentrations) as a function of O 2 fractional saturation. Unlike hHb which shows a bell-shaped dependence of initial rate against fractional saturation [21, 23] , the initial rate for nitrite-reduction by HBOC-201 shows a significant inverse and linear relationship against fractional saturation. This is reflected in a similar profile for the rate constant, which also significantly increases as fractional saturation decreases. Consistent with nitrite-reduction, NO was a product of nitrite deoxy-HBOC-201 reactions as determined by formation of nitrosyl-HBOC-201 ( Figure 1E) , which increased at lower fractional saturations, and by the formation of free NO under anoxic conditions ( Figure 1F ). The latter was confirmed by loss of signal in response to the NO scavenger cPTIO as shown in Figure 1(F) .
Effects of hHb and HBOC-201 oxygen fractional saturation on NOand nitrite-mediated vasodilation of aortic rings
To assess if nitrite-reduction by HBOC-201 regulates NO signalling we employed the experimental model of vasodilation of isolated aortic rings as described previously in [24] . This approach, which provides a sensitive read-out of NOdependent signalling (i.e. vasodilation) is amenable to performing experiments at different oxygen tensions and hence HBOC-201 fractional saturations. We next tested the effects of HBOC-201 and hHb on nitritedependent vasodilation. Consistent with previous studies [24, 29] showing a role for NO in nitrite-mediated vasodilation, hHb inhibited vasodilation at high (2, 21 and 95 %) O 2 fractional saturations (see Supplementary Results and Supplementary Figure S1 at http://www.BiochemJ.org/bj/422/bj4220423add.htm). Under deoxygenated conditions, however, hHb failed to inhibit nitrite-dependent vasodilation. We have shown previously that this failure to inhibit NO-dependent effects at lower fractional saturations can be explained by the nitrite reductase activity of deoxyhaemoglobin, with the resultant NO formation counteracting haem-based NO scavenging [24] . Supplementary Figure S1 shows results from experiments testing the effects of HBOC-201 on nitrite-dependent vasodilation. However, in the course of these experiments it was noted that in the presence of nitrite, the concentration of HBOC-201 was decreasing, particularly at higher oxygen tensions. A systematic evaluation of HBOC-201 concentration as a function of time demonstrated that the HBOC-201 concentration decreased ∼ 40 % during the course of nitrite-dependent vasodilation experiments at both 95 and 21 % O 2 (see Supplementary Figure  S2A at http://www.BiochemJ.org/bj/422/bj4220423add.htm). Interestingly, nitrite had no effect on the concentration of hHb (see Supplementary Figure S2A ) and the loss of HBOC-201 did not occur in the presence of MNO (see Supplementary  Figure S2B ), suggesting a specific interaction between nitrite, higher oxygen tensions and HBOC-201 that leads to HBOC-201 decomposition. The changing HBOC-201 concentration during these experiments precludes interpretation of effects on nitrite-dependent vasodilation. We therefore employed a modified protocol in which the vasodilatory effects of single doses of nitrite were assessed in the presence or absence of HBOC-201. Using this protocol, which resulted in nitrite/HBOC-201 incubation times of 3.9 + − 0.4 min (mean + − S.E.M.; n = 7) compared with 38.1 + − 1.4 min (mean + − S.E.M.; n = 17) for nitrite-dose cumulative studies (see Supplementary Figure S1 ), no significant loss of HBOC-201 occurred at any oxygen tension (results not shown). Figure 4 shows that using this approach HBOC-201 significantly inhibited nitrite-dependent vasodilation at 95 and 21 % O 2 , but did not affect nitrite-dependent vasodilation at either 2 or 0 % O 2 . Consistent with these results, nitrite increased cGMP levels to similar extents both in the absence and presence of HBOC-201 at 0 % O 2 ( Figure 5 ).
Nitrite administration attenuates HBOC-201-mediated hypertension during trauma-haemorrhage
We next tested if nitrite therapy could prevent HBOC-201-mediated hypertension in a murine model of traumahaemorrhagic shock and resuscitation. Consistent with previous studies [33, 36] , resuscitation with HBOC-201 increased MAP above prehaemorrhage levels, underscoring its hypertensive effects ( Figures 6A and 6B) . However, in a dose-dependent manner, one bolus administration of nitrite immediately before resuscitation prevented HBOC-201-mediated hypertension (Figure 6A) , with MAP returning to prehaemorrhage levels with 30 nmol nitrite ( Figures 6B and 6E ). (Table 1) . This indicated that nitrite can improve haemodynamics without affecting the O 2 and CO 2 carrying functions of haemoglobin (Table 1) . To assess the safety of nitrite administration we measured changes in MAP, methaemoglobin and serum levels of HBOC-201. Table 1 shows that nitrite administered at this dose, which was able to normalize hypertension, did not cause any loss of HBOC-201.
DISCUSSION
Previous developments have highlighted the potential for NO formation from haemoglobin and nitrite in mediating vascular function and offering a novel therapeutic strategy to attenuate hypertensive effects of HBOCs [13, 20, 21, 25, [33] [34] [35] [40] [41] [42] [43] . HBOC-201 was chosen as a model HBOC for the present work because it has been extensivly studied. The aim was to evaluate the nitrite reductase activity of HBOC-201 and test if NO derived from this process is capable of maintaining NO-dependent vasodilation both ex vivo, by aortic ring studies, and in vivo, during traumahaemorrhage and resuscitation.
The differential reactivities of oxyhaemoglobin and deoxyhaemoglobin with nitrite have been acknowledged for many years [27] , with oxyhaemoglobin oxidizing nitrite to nitrate and deoxyhaemoglobin reducing nitrite to NO. Recent insights into the mechanisms of this oxygen-linked reactivity of haemoglobin have shown that nitrite reduction is modulated via allosteric regulation of haemoglobin conformation states (R-or T-states) [21] [22] [23] . Specifically, the rate of nitrite reduction by haemoglobin shows a bell-shaped dependence on fractional saturation, with the maximum around the haemoglobin p50. This property has been demonstrated with cell-free and erythrocytic hHb [21, 23] , rabbit [44] , murine and most recently adult and fetal sheep haemoglobin [45] . The importance of p50 in nitrite reduction can be explained by considering that the rate is controlled by firstly, the availability of deoxyhaems for nitrite binding and secondly, by the average intrinsic haem redox potential. A more negative redox potential, associated with R-state haemoglobin, facilitates electron transfer and results in increased rate constants for nitrite reduction. Additional factors have been suggested to control the nitrite reductase activity, including steric factors that regulate haem accessibility for nitrite [46] and mechanisms that regulate how nitrite may enter the RBC [32] . Consistent with the hypothesized faster rates of nitrite reduction by R-state deoxyhaem, fetal haemoglobin, which is more R-state compared with adult haemoglobin, reduces nitrite approx. 2-fold faster than adult haemoglobin [45] . Increasing additions of PEG [poly(ethylene glycol)] chains to cross-linked haemoglobin also increases the rate constant for nitrite reduction in a manner proportional to the R-state character [35] .
HBOC-201 represents an interesting haemoglobin with respect to nitrite reduction as it is T-state stabilized, resulting in a higher p50, a therapeutic goal that improves oxygen delivery [47] . Extrapolating from the results shown in Figure 1(D) , the rate constant for nitrite reduction by fully deoxygenated HBOC-201 is 0.25 M −1 · s −1 at 37 • C. Reported rate constants [40] for either deoxygenated cell-free hHb or cell-free sheep haemoglobin at 25
• C are 0.25
respectively. Considering that these numbers were obtained at 25
• C, it is reasonable to expect that these reaction rates will be higher at 37
• C. As a result we propose that the rate constant for nitrite reduction by HBOC-201 is lower compared with either deoxygenated cell-free hHb or cell-free sheep haemoglobin, consistent with T-state character of HBOC-201. This is further reflected in the dependence of the rate constant and initial rate of nitrite reduction on HBOC-201 O 2 fractional saturation. For native haemoglobin the rate constant for nitrite reduction increases with fractional saturation paralleling R-state configuration [21, 23] . With HBOC-201 however the rate constant was linear and inversely proportional to the O 2 fractional saturation, a relationship that was also observed with the initial rate ( Figure 1D ). Whereas the increased initial rate is expected based on deoxyhaem concentrations, the mechanistic basis for the observed increase in the rate constant for nitrite reduction with HBOC-201 deoxygenation remains unclear. We have not measured the nitrite reductase kinetics of native bovine haemoglobin precluding comparison of HBOC-201 with the unmodified, and non-T-state stabilized, control. It also should be noted that we cannot exclude the possibility that steric effects, introduced by glutaraldehyde modification, could be responsible. However, the results presented underscore the potential to modulate the nitrite reductase activity of any given HBOC by both controlling deoxyhaem concentrations (p50) and the intrinsic rate constant for nitrite reduction (R-or T-state character).
Importantly, we also observed NO formation from the nitritedeoxyHBOC-201 reaction ( Figures 1E and 1F) . Recent insights suggest that nitrite reduction to NO occurs via the intermediate formation of N 2 O 3 , secondary to methaem-nitrite reactions with NO [48] . We have not explored this mechanism in the present study as we are focusing specifically on the ability of HBOC-201 to produce NO from nitrite and evaluate the potential of this process in mediating vascular NO-dependent signalling. The latter was assessed by using isolated aortic ring bioassays. We employed an experimental design that allows the testing of how the interplay between nitrite, NO and HBOC-201 at different fractional saturations affect the nitrite-dependent vasodilation. Consistent with our previous study [24] , hHb inhibited MNOdependent vasodilation at all the tested fractional saturations due to rapid haem-based NO scavenging. These observations were reprised with HBOC-201, supporting NO scavenging as the primary mechanism by which this modified haemoglobin causes hypertension. With nitrite, hHb inhibited relaxation only at high O 2 fractional saturations, with deoxygenated hHb having no effect. We have shown previously [40] that nitrite-dependent vasodilation, at all the oxygen tensions tested, is mediated through NO formation and interpreted the lack of an inhibitory effect of deoxygenated hHb as evidence for a counterbalancing formation of NO at low oxygen tensions via nitrite-reduction. A similar response was observed with HBOC-201 (Figure 3 ). Interestingly, we had to employ a modified bolus-addition protocol to assess the effects of HBOC-201 fractional saturation on nitrite-meditated vasodilation. This was in order to mitigate the significant loss of HBOC-201 that was observed in cumulative nitrite dosedependent experiments, predominantly at high oxygen tensions, and was specific to HBOC-201 and nitrite. It is probable that HBOC-201 decomposition occurs secondary to protein denaturation. The latter has been documented to especially occur when haemoglobin undergoes redox cycling reactions that lead to an intermediate population of higher haem oxidation states and free radicals [3, 6] (e.g. ferryl and ferryl-associated free radicals [3] ) that can lead to formation of inter-and intra-molecular crosslinks and, ultimately, haem and protein degradation. Likewise, the reaction of nitrite with oxygenated haemoglobin involves haem redox cycling and formation of protein based radicals [49] and higher nitrogen oxides; all these may also contribute to HBOC-201 denaturation. We have not tested this hypothesis in the present study and highlight these denaturation results as any potential interaction that leads to HBOC denaturation will not only limit therapeutic efficacy of HBOC-201 but may contribute to tissue injury, through release of free iron and generation of reactive species. It is therefore important to bring attention to the possibility of a toxic effect of high-dose nitrite and HBOC-201 therapy and the potential need for use of supplemental oxygen in situations when nitrite and HBOC-201 are co-administered. We, however, note that in our in vivo studies (see discussion below) no evidence of HBOC-201 decomposition due to an interaction with nitrite therapy was observed (Table 1) . Moreover, the doses of nitrite used in vivo that attenuate HBOC-201-dependent hypertension are lower than the doses achieved in ex vivo cumulative dose-dependent vasodilation studies, with an approx. final dose of 100 μM.
Biochemical and ex vivo vasodilation studies suggested that HBOC-201-mediated nitrite reduction and NO formation may be harnessed to prevent vasoconstriction in vivo. To test this hypothesis we used a murine model of trauma, controlled haemorrhage and resuscitation. Consistent with previous reports [33, 36] , normovolemic resuscitation with HBOC-201 led to a mild but significant hypertensive response of approx. 8 mmHg. This response remains at the centre of the proposed toxicity associated with administration of HBOCs and has thus far largely limited translation of these compounds into front-line clinical resuscitative agents. Normalizing HBOC-201-mediated hypertension therefore remains a key therapeutic goal. The results in the present study show that at a low dose, of <30 nmol, nitrite is able to prevent HBOC-201-mediated hypertension. These results do not exclude the possibility that nitrite may stimulate NO signalling by haemoglobin independent, tissue dependent mechanisms [28, 50] . However, the observation that 30 nmol nitrite failed to affect MAP with LR resuscitation, but did promote a hypotensive effect with HBOC-201 resuscitation, suggests that nitrite reaction with HBOC-201 redresses the balance for NO signalling in vivo.
Nitrite dose-response results also demonstrate the presence of a therapeutic window in which nitrite can be administered during HBOC-201 resuscitation. Nitrite administration prevented hypertension without causing hypotension at concentrations between 10 and 30 nmol ( Figure 6E ). Other concerns with the use of nitrite as a therapy include formation of methaemoglobin, which would compromise oxygen delivery and potentially contribute to haem-based oxidative stress. However, within the nitrite dose range in which hypertension was attenuated without causing hypotension, methaemoglobin only increased 2-3 %, which importantly was not different to the increase observed in the absence of nitrite. Also, no differences in methaemoglobin formation with nitrite doses of 0-100 nmol were observed, suggesting that increased methaemoglobin formation at the expense of ferrous haem, which rapidly scavenges NO [12] , is unlikely to account for the nitrite dose-dependent attenuation of hypertension. Using 30 nmol nitrite resulted in nitrite levels at end of resuscitation that were higher than the basal levels but still relatively low (∼ 1 μM). Within 2 h of resuscitation nitrite levels decrease to baseline, consistent with a relatively short halflife of nitrite in the mammalian circulation (∼ 10-30 min) [18] , a property that would further limit potential toxicity of nitrite administration.
In summary, we present results that support the use of nitrite as an adjunct therapy to attenuate HBOC-dependent hypertension. We propose that HBOC-mediated nitrite reduction counters NO scavenging and hypertensive effects. These results further support the notion that the effectiveness of using any HBOC as a nitrite reductase in vivo can be affected by either altering the oxygen affinity and/or the intrinsic nitrite reductase activity. Relative to other α-chain cross-linked haemoglobins [35] , HBOC-201 is a slower nitrite reductase (i.e. it has a lower rate constant for the nitrite reductase activity). However, we speculate that due to its high p50, sufficient deoxygenation occurs in vivo to sustain significant nitrite reductase activity. These results underscore that the potential flexibility afforded by the ability to influence nitrite reductase activity, by altering intrinsic redox potential and/or oxygen affinity, may be critical in the therapeutic development of the next generation of HBOCs. resuscitation); and (iv) 240 min after initiation of experiment (corresponding to end of experiment). The samples were measured as described in the Experimental section in the main paper.
RESULTS
Effects of HBOC-201 and hHb in nitrite-dependent vasodilation
hHb inhibited nitrite-dependent vasodilation at all oxygen tensions that resulted in hHb oxygenation (95, 21 and 2 % O 2 ). This result can be explained by NO scavenging as previously reported [12] . However, when hHb was significantly deoxygenated, with a fractional O 2 saturation of approx. 25 %, at 0% O 2 hHb did not affect the nitrite-dependent vasodilation. We have suggested previously [24] that this effect may be explained by deoxyhaemoglobin-mediated nitrite reductase activity resulting in NO generation, which counters the NO scavenging processes. HBOC-201 showed a similar reactivity at O 2 tensions that result in deoxygenation. Surprisingly, however, at 95 and Figure S2A) . This decrease in haem will in turn decrease the rate of both the NO scavenging and the nitrite oxidation kinetics. It also may explain the apparent lack of inhibition of nitrite-dependent vasodilation by oxyHBOC-201. Supplementary Figure S2 (A) also shows that no loss of hHb is observed during these studies. Supplementary Figure S2 (B) shows that no loss of HBOC-201 occurs during MNO-vasodilation experiments.
